Editas Medicine, Inc. (EDIT - Free Report) was a big mover last session, as its shares rose over 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $15.45 to $18.86 in the past one-month time frame.
The company has seen one positive estimate revision in the last 30 days and its Zacks Consensus Estimate has moved higher over the said time frame, suggesting solid trading ahead. So make sure to keep an eye on this stock going forward to see if Friday’s jump can turn into more strength down the road.
Editas Medicine currently carries a Zacks Rank #3 (Hold).
A better-ranked stock worth considering in the Medical - Biomedical and Genetics space is Alexion Pharmaceuticals, Inc. sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is EDIT going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Editas Medicine, Inc. (EDIT - Free Report) was a big mover last session, as its shares rose over 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $15.45 to $18.86 in the past one-month time frame.
The company has seen one positive estimate revision in the last 30 days and its Zacks Consensus Estimate has moved higher over the said time frame, suggesting solid trading ahead. So make sure to keep an eye on this stock going forward to see if Friday’s jump can turn into more strength down the road.
Editas Medicine currently carries a Zacks Rank #3 (Hold).
A better-ranked stock worth considering in the Medical - Biomedical and Genetics space is Alexion Pharmaceuticals, Inc. sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is EDIT going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on EDIT - FREE